Loading market dashboard
Ultragenyx Pharmaceutical Inc.
RAREHealthcareNASDAQUS
Loading analysis workspace
Estimates, scoring, valuation assumptions, and peer comparison in one research surface.
Ultragenyx Pharmaceutical Inc. · Forecast overview
Bars show expected revenue while the line tracks expected EPS.
| Period | Revenue avg | Revenue range | EBITDA | EPS avg | Analysts |
|---|---|---|---|---|---|
| Dec 2030 | $2.12B | $1.84B - $2.87B | -$1.95B | $5.327 | 6 |
| Dec 2029 | $1.58B | $1.37B - $2.14B | -$1.45B | $2.819 | 12 |
| Dec 2028 | $1.20B | $1.19B - $1.21B | -$1.10B | $0.504 | 13 |
| Dec 2027 | $983.52M | $744.59M - $1.48B | -$900.92M | -$0.699 | 13 |
| Dec 2026 | $741.44M | $729.34M - $767.09M | -$679.17M | -$4.483 | 13 |
| Dec 2025 | $664.69M | $661.68M - $675.62M | -$608.87M | -$5.60 | 10 |
| Dec 2024 | $547.60M | $537.79M - $557.11M | -$501.61M | -$6.191 | 11 |
| Dec 2023 | $481.30M | $417.88M - $651.24M | -$440.88M | -$7.229 | 9 |
| Dec 2022 | $361.74M | $325.61M - $389.82M | -$375.95M | -$9.922 | 4 |
| Dec 2021 | $351.78M | $316.64M - $379.08M | -$355.54M | -$6.254 | 5 |
| Dec 2020 | $250.02M | $225.04M - $269.42M | -$101.61M | -$3.794 | 5 |
| Dec 2019 | $100.42M | $90.39M - $108.22M | -$367.46M | -$6.938 | 4 |